Concomitant short‐ and long‐duration response to levodopa in the 6‐OHDA‐lesioned rat: a behavioural and molecular study

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Neuroscience

• Publication date

  2007-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1460-9568.2006.05265.xPMID 17241287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synapse

  2009cited by this paper
• Reversion of levodopa‐induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6‐OHDA‐lesioned rats

  2006cited by this paper
• Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia

  2005cited by this paper
• Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.

  2005cited by this paper
• Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

  2005cited by this paper
• Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

  2005cited by this paper
• Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

  2005cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

  2004cited by this paper
• Upregulation of striatal adenosine A2A receptor mRNA in 6‐hydroxydopamine‐lesioned rats intermittently treated with L‐DOPA

  2004influential reference
• Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa.

  2004cited by this paper
• Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.

  2003cited by this paper
• Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

  2003cited by this paper
• Apomorphine Infusion and the Long-Duration Response to Levodopa in Advanced Parkinson's Disease

  2003cited by this paper
• Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa.

  2003cited by this paper
• The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.

  2003cited by this paper
• Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa‐induced neurochemical changes within the basal ganglia and on levodopa‐induced motor alterations in 6‐hydroxydopamine‐lesioned rats

  2003cited by this paper
• Dual effects of intermittent or continuous L‐DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6‐OHDA lesion

  2003cited by this paper
• Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.

  2003cited by this paper
• Evolution of the response to levodopa during the first 4 years of therapy

  2002cited by this paper
• Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• MK‐801 alters the effects of priming with L‐DOPA on dopamine D1 receptor‐induced changes in neuropeptide mRNA levels in the rat striatal output neurons

  2002cited by this paper
• LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa‐induced motor alterations in Parkinsonian rats

  2001cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life

  2001cited by this paper
• Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

  2001cited by this paper
• Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.

  2001cited by this paper
• Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD

  2000cited by this paper
• Involvement of the direct striatonigral pathway in levodopa‐induced sensitization in 6‐hydroxydopamine‐lesioned rats

  2000cited by this paper
• Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion

  2000cited by this paper
• CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.

  2000cited by this paper
• Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.

  2000cited by this paper
• Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.

  2000cited by this paper
• Systemic Administration of NMDA and AMPA Receptor Antagonists Reverses the Neurochemical Changes Induced by Nigrostriatal Denervation in Basal Ganglia

  1999cited by this paper
• Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

  1999cited by this paper
• Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists

  1999cited by this paper
• Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

  1999cited by this paper
• Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

  1999influential reference
• Adenosine receptors and Parkinson's disease

  1999cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.

  1998cited by this paper
• Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  1998cited by this paper
• The long-duration action of levodopa may be due to a postsynaptic effect.

  1997cited by this paper
• Long‐duration response to levodopa influences the pharmacodynamics of short‐duration response in Parkinson's disease

  1997cited by this paper
• Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.

  1997cited by this paper
• Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat.

  1997cited by this paper
• Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

  1997cited by this paper
• MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.

  1996cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.

  1995cited by this paper
• Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum.

  1995cited by this paper
• The subacute levodopa test for evaluating long‐duration response in parkinson's disease

  1995cited by this paper
• Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.

  1995cited by this paper
• Long-duration response to levodopa

  1995cited by this paper
• Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.

  1994cited by this paper
• Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.

  1994cited by this paper
• NMDA receptor blockade reverses motor response alterations induced by levodopa.

  1994cited by this paper
• Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis

  1991cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper

• Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

  2025cites this paper
• Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease

  2017cites this paper
• CHARACTERIZATION OF GREY MATTER ATROPHY FOLLOWING 6-HYDROXYDOPAMINE LESION OF THE NIGROSTRIATAL SYSTEM

  2016cites this paper
• Characterization of nociceptive response to chemical, mechanical, and thermal stimuli in adolescent rats with neonatal dopamine depletion.

  2015cites this paper
• Effects of acute and chronic dopaminergic treatment on motor and non-motor function in the hemi-Parkinsonian rat

  2014cites this paper
• The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.

  2013cites this paper
• Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.

  2012cites this paper
• Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.

  2012cites this paper
• Running Head : TIME-COURSE OF MOTOR DEFICITS 1 Time-course of Motor Deficits in a Rat Model of Parkinson ’ s Disease

  2012cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.

  2010cites this paper
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats

  2009influential citation
• Molecular basis of L-DOPA-induced dyskinesia : Studies on striatal signaling

  2009cites this paper
• Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.

  2008cites this paper
• Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.

  2008influential citation
• The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

  2008cites this paper
• THE INFLUENCE OF INTERMITTENT L-DOPA TREATMENT ONSTRIATAL MOLECULAR MARKERS IN HEMIPARKINSONIANRATS*

  2008cites this paper
• THE INFLUENCE OF INTERMITTENT L-DOPA TREATMENT ON STRIATAL MOLECULAR MARKERS IN HEMIPARKINSONIAN RATS* VPLIV INTERMITENTNEGA DAJANJA L-DOPA NA STRIATNE MOLEKULSKE OZNAČEVALCE PRI HEMIPARKINSONSKIH PODGANAH

  2008cites this paper